IL309251A - Norepinephrine reuptake inhibitors for the treatment of sleep apnea - Google Patents

Norepinephrine reuptake inhibitors for the treatment of sleep apnea

Info

Publication number
IL309251A
IL309251A IL309251A IL30925123A IL309251A IL 309251 A IL309251 A IL 309251A IL 309251 A IL309251 A IL 309251A IL 30925123 A IL30925123 A IL 30925123A IL 309251 A IL309251 A IL 309251A
Authority
IL
Israel
Prior art keywords
sleep apnea
reuptake inhibitors
norepinephrine reuptake
treating sleep
treating
Prior art date
Application number
IL309251A
Other languages
English (en)
Hebrew (he)
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of IL309251A publication Critical patent/IL309251A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL309251A 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for the treatment of sleep apnea IL309251A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211673P 2021-06-17 2021-06-17
US202263319035P 2022-03-11 2022-03-11
PCT/US2022/033987 WO2022266440A1 (en) 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for treating sleep apnea

Publications (1)

Publication Number Publication Date
IL309251A true IL309251A (en) 2024-02-01

Family

ID=82608262

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309251A IL309251A (en) 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for the treatment of sleep apnea

Country Status (10)

Country Link
US (1) US20240277719A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355333A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523876A (cg-RX-API-DMAC7.html)
KR (1) KR20240021920A (cg-RX-API-DMAC7.html)
AU (1) AU2022294086A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023026158A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221848A1 (cg-RX-API-DMAC7.html)
IL (1) IL309251A (cg-RX-API-DMAC7.html)
MX (1) MX2023014709A (cg-RX-API-DMAC7.html)
WO (1) WO2022266440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CN119185558A (zh) * 2017-04-28 2024-12-27 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
CN111670050A (zh) * 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
CA3117766A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
ES3049086T3 (en) * 2019-02-08 2025-12-12 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
KR20240021920A (ko) 2024-02-19
EP4355333A1 (en) 2024-04-24
MX2023014709A (es) 2024-01-15
US20240277719A1 (en) 2024-08-22
WO2022266440A1 (en) 2022-12-22
CA3221848A1 (en) 2022-12-22
BR112023026158A2 (pt) 2024-03-05
JP2024523876A (ja) 2024-07-02
AU2022294086A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
GEP20247617B (en) Methods and compositions for treating sleep apnea
CA208377S (en) Mouth tape for treating sleep disorders
GB202309744D0 (en) New treatments for pain
CA208374S (en) Mouth tape for treating sleep disorders
IL276247A (en) Methods and materials for the treatment of sleep apnea
BRPI0916614A2 (pt) implantes magnéticos para o tratamento de apneia obstrutiva do sono
EP2237745A4 (en) PARTLY ESTABLISHABLE SYSTEMS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA
EP2291152A4 (en) PARTIALLY ERODABLE SYSTEMS FOR THE TREATMENT OF AN OBSTRUCTIVE APNEA OF SLEEP
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL294594A (en) Methods of treating pemphigus
IL300584B1 (en) Internal ultraviolet therapy
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
AU2022298632A1 (en) Methods for treating obstructive sleep apnea
IL310394A (en) Corona virus inhibitors
ZA202106233B (en) Method of improving sleep
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
BR112012000614A8 (pt) métodos e composições para o tratamento de condições médicas relacionadas a tireóide com folatos reduzidos
IL291146A (en) Treatment of hidradenitis with jak inhibitors
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
CA208375S (en) Mouth tape for treating sleep disorders
CA208376S (en) Mouth tape for treating sleep disorders
HK40109751A (en) Norepinephrine reuptake inhibitors for treating sleep apnea
IL313648A (en) Combination of a TASK1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea
IL201430A0 (en) Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep related breathing disorders
UA102874C2 (uk) Застосування рацемату піноцембрину у приготуванні лікарського препарату для лікування удару